Skip to main content

Grail

GRAIL Inc is an American healthcare and biotechnology company developing blood tests for early cancer detection. The company utilizes high-intensity methylation sequencing, machine learning algorithms, and circulating tumor DNA science to identify multiple cancer types from single blood samples. Main revenue drivers include commercial sales of the Galleri multi-cancer early detection blood test and biopharmaceutical clinical research partnerships. GRAIL serves healthcare systems, self-insured employers, medical practitioners, and biopharmaceutical development partners across the United States and international markets. The company holds a pioneer position in multi-cancer early detection testing technology using liquid biopsy platforms. Headquartered in Menlo Park, California, GRAIL Inc is listed on the Nasdaq Stock Market.

7 of the funds FundTelligence covers report a position in Grail.

Legal name
GRAIL Inc
Sector
Health Care
Country
United States
Funds holding it
7
Exposure themes
Molecular Diagnostics, Multi-Cancer Early Detection, Precision Medicine & Genomics

Funds holding Grail

Loading...